BridgeBio is substantially advanced the course of the novel solution for amyloid heart disease, leveraging the investigational drug. Initial patient information indicates potential benefits for patients affected from https://attr-cm638669.blogitright.com/42465629/firm-advances-amyloidosis-therapy-with-the-therapy